WELCOME TO The PHARMACEUTICAL REPORT
Denk Pharma GmbH & Co. KG
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Hovione | February 23, 2022
Hovione, the leader in spray drying and particle engineering, announced a strategic partnership with Zerion Pharma to market and commercialize Dispersome®, Zerion´s proprietary solubility enhancement technology platform.
Zerion´s innovative Dispersome® technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions (ASDs) by spray drying. By combining Dispersome® t...
openPR | April 09, 2020
Stratagem Market Insights has announced the addition of the "Active Pharma Ingredient Market Report 2020-2027 Production, Sales And Consumption Status And Prospects Professional Research", The report classifies the global Active Pharma Ingredient Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. Active Pharmaceutical Ingredient (API) produces the intended effects in a drug. A drug can contain a singl...
Commonwealth Informatics, a Genpact company | January 25, 2022
Commonwealth Informatics, an independently-operated subsidiary of Genpact, and leading technology and services company with industry expertise in medical product safety and public health surveillance, today announced that it has expanded its relationship with the Medicines and Healthcare products Regulatory Agency, a medical regulatory body for the United Kingdom.
MHRA has selected Commonwealth Informatics' state-of-the-art signal detection and signal management solution, Comm...
Atara Biotherapeutics, Inc. | October 04, 2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America.
Under the terms of the agreement, Atara will receive an upfront payment of USD 45 million, and...
BUSINESS INSIGHTS, VIEWS AND ANALYSIS
VIEWS AND ANALYSIS, PHARMACY MARKET
BUSINESS INSIGHTS, PHARMACY MARKET
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE